Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art

Title:Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art

Volume: 1

Author(s): Lisa Salvatore, Fotios Loupakis, Andrea Ciarlo, Chiara Cremolini, Camilla Comin, Marta Schirripa, Luca Messerini, Federica Marmorino, Carlotta Antoniotti and Alfredo Falcone

Affiliation:

Keywords: Metastatic colorectal cancer, liver resection, preoperative chemotherapy, bevacizumab, FOLFOXIRI, complete pathologic response.

Abstract: A 61-year-old white man presented with a stenosing tumour of the right colon and a large hepatic metastasis measuring 90 mm in its largest diameter, judged not suitable for immediate resection. He underwent right hemicolectomy and received 12 cycles of treatment with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) plus bevacizumab. According to Response Evaluation Criteria in Solid Tumors (RECIST criteria), he achieved a partial response that allowed a secondary radical hepatic resection. Pathologic examination of the liver specimen showed the absence of residual tumour cells: a pathologic complete response (pCR) was achieved. In this case, an intensive up-front treatment (i.e. the combination of FOLFOXIRI plus bevacizumab) produced the pCR of a liver metastasis from colorectal cancer despite its initial large dimension while confirming the possible discrepancy between radiologic assessment and pathological findings.

Cite this article as:

Salvatore Lisa, Loupakis Fotios, Ciarlo Andrea, Cremolini Chiara, Comin Camilla, Schirripa Marta, Messerini Luca, Marmorino Federica, Antoniotti Carlotta and Falcone Alfredo, Case-Report: Folfoxiri Plus Bevacizumab in “Poor-Risk” Liver-Only Metastatic Colorectal Cancer: Case Report and State-of-the-Art, Clinical Cancer Drugs 2014; 1 (1) . https://dx.doi.org/10.2174/2212697X0101131204152941